Figure 4From: Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer Overall response rates*. * The test for subgroup differences is only possible using the fixed effect model in RevMan. The difference in relative risks between figure 3 and 4 is due to the fact that the random effects model gives relatively more weight to smaller trials.Back to article page